diagnosis: MS. A New Era of MS Therapies?

October 2010
PN;Oct2010, Vol. 64 Issue 10, p16
Trade Publication
The article focuses on the new multiple sclerosis (MS) drugs such as Gilenia from Novartis AG and Movectro from Merck Serono International SA which acquired a Russian approval. It says that Movectro has become a leading oral MS drug as compared to Gilenia, though Gilenia has been recommended by the U.S. Food & Drug Administration (FDA) as a first-line therapy. It suggests that the Movectro's approval offers greater market opportunities and larger market share.


Related Articles

  • research update. MS Spasticity: Take Control! Hugos, Cinda // PN;Dec2010, Vol. 64 Issue 12, p40 

    The article offers the author's insights on multiple sclerosis (MS) spasticity management. It states that the author, along with Lois Copperman and the National MS Society, has developed a DVD program on spasticity guideline titled "MS Spasticity: Take Control." It mentions that the DVD program...

  • Oral drug approved for relapsing multiple sclerosis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788 

    The article reports on the approval of Novartis AG's fingolimod, a podrug of sphingosine 1-phosphate receptor modulator, for treating patients with relapsing forms of multiple sclerosis by the U.S. Food & Drug Administration (FDA). It looks at how such drug aids in reducing the severity of...

  • Reexamining the evidence for inpatient glucose control: New recommendations for glycemic targets. Moghissi, Etie S. // American Journal of Health-System Pharmacy;8/15/2010 Supplement, Vol. 67, pS3 

    Purpose. To review the risks of hyperglycemia in hospitalized patients, data supporting the benefits of treating hyperglycemia, and recommendations from the 2009 American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on the management of inpatient...

  • New ARB Outperforms Older Agents.  // American Health & Drug Benefits;May/Jun2010, Vol. 3 Issue 3, p210 

    The article presents results from a study presented at the 2010 American Society of Hypertension (ASH) conference that compared the effectiveness of the angiotensin receptor blocker (ARB) azilsartan to olmesartan and valsartan in lowering blood pressure.

  • MS SERIES 7. Relapse management strategies in multiple sclerosis: Theories and practice. Burgess, Megan // British Journal of Neuroscience Nursing;Aug/Sep2010, Vol. 6 Issue 6, p276 

    Relapses are experienced by 85-90% of people at and following onset of multiple sclerosis, as a feature of their disease (Lublin and Reingold, 1996). There is a great deal of uncertainty and variation with regards to presentation, duration and frequency of recurrence of relapses which varies for...

  • readers respond. Formulary and Fatigue. Wright, Lawrence J. // PN;Nov2010, Vol. 64 Issue 11, p11 

    A letter to the editor regarding the treatment of multiple sclerosis is presented.

  • Safety concerns may speak to need for judicious anti-VEGF use. Boyle, Erin L.; Bechtel, Bryan; Hasson, Matt; Master, Joe; Mullin, David W.; Regillo, Carl D. // Ocular Surgery News;11/25/2010, Vol. 28 Issue 22, p22 

    No abstract available.

  • Topical steroid trial may predict IOP response after intravitreal triamcinolone. Bechtel, Bryan; Hasson, Matt // Ocular Surgery News;11/25/2010, Vol. 28 Issue 22, p32 

    No abstract available.

  • Anti-VEGF injection regimen for AMD still unclear, speaker says.  // Ocular Surgery News;10/10/2010, Vol. 28 Issue 19, p33 

    The article discusses research done on anti-vascular endothelial growth factor (VEGF) therapy in age-related macular degeneration, presented by Doctor Frank Holz at the Euretina Congress that was held from September 2 to 5, 2010 in Paris, France.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics